Medical treatment of second-trimester fetal miscarriage; A retrospective analysis

PLoS One. 2017 Jul 28;12(7):e0182198. doi: 10.1371/journal.pone.0182198. eCollection 2017.

Abstract

Objectives: Research on the treatment of second-trimester miscarriages is scarce. We studied the outcomes, and the factors associated with adverse events and need for hospital resources in the medical treatment of second-trimester miscarriage.

Materials and methods: In these retrospective analyses we studied women treated for spontaneous fetal miscarriage with misoprostol-only (n = 24) or mifepristone and misoprostol (n = 177) in duration of gestation 12+1-21+6. Primary outcomes were the risk factors for surgical evacuation and excessive bleeding. Secondary outcomes were total misoprostol dose, time to expulsion and the length of hospital stay.

Results: History of surgical evacuation of the uterus increased the risk of surgical evacuation (p = 0.027). Excessive bleeding was not associated with any of the studied variables. More misoprostol was needed when the duration of gestation exceeded 17+0 weeks (p = 0.036). In multivariate analysis the time to fetal expulsion was shorter in women with history of 1-2 deliveries (hazard ratio [HR] 1.49, 95% confidence interval [CI]; 1.07-2.07), ≥3 deliveries (HR 1.63, 95% CI; 1.11-2.38) and with a two-day interval between mifepristone-misoprostol administration (HR 1.71, 95% CI; 1.05-2.81). Patients with symptoms (i.e. uterine bleeding or pain) at baseline had longer hospital stay (HR 0.66, 95% CI; 0.47-0.92).

Conclusions: The factors affecting the outcomes of medical treatment of second-trimester fetal miscarriage are similar to those of second-trimester induced abortion. Two-day interval between mifepristone-misoprostol administration might decrease the time to fetal expulsion and the need of hospital resources.

MeSH terms

  • Abortion, Spontaneous / drug therapy*
  • Adult
  • Drug Administration Schedule
  • Female
  • Humans
  • Length of Stay / statistics & numerical data
  • Mifepristone / administration & dosage
  • Mifepristone / therapeutic use*
  • Misoprostol / administration & dosage
  • Misoprostol / therapeutic use*
  • Pregnancy
  • Pregnancy Trimester, Second
  • Retrospective Studies

Substances

  • Misoprostol
  • Mifepristone

Grants and funding

The authors received no specific funding for this work.